Osagie Imasogie
Osagie ImasogieCEO | Chairman | Director
Osagie Imasogie has over 35 years of experience in the pharmaceutical and healthcare industries, serving in multiple capacities, including business management, law and finance, and currently serves as a co-founder and Senior Managing Partner of PIPV. During his time at PIPV, Mr. Imasogie has been a co-founder and Chairman of the board of several pharmaceutical companies, including Iroko Pharmaceuticals, LLC, Churchill Pharmaceuticals LLC, Ception Therapeutics, Inc. and Trigenesis Therapeutics Inc.
In addition, he serves on the board of a number of financial institutions such as FS KKR Capital Corp. (NYSE: FSK) ($16 billion in assets under management), Haverford Trust Company (over $9.9 billion in assets under management) and Beltraith Advisors/StoneRidge Investments (over $2 billion in assets under management).
Prior to PIPV, Mr. Imasogie conceptualized and established GlaxoSmithKline Ventures and was its founding Vice President. Mr. Imasogie led GSK Ventures in concluding over 30 worldwide transactions within a 3-year period, in which he invested various GlaxoSmithKline (LSE: GSK) R&D non-progressed assets into various companies as the basis of starting new companies. Prior to GlaxoSmithKline, Mr. Imasogie was a Vice President for Product Development Strategy at SmithKline Beecham. Prior to SmithKline, Mr. Imasogie was the Founding Senior Vice President for Business Development and General Counsel at Endo Pharmaceuticals, Inc. (Nasdaq: ENDP), a publicly traded company with a peak market capitalization of $18 billion. Mr. Imasogie previously served as a DuPont Merck Vice President for International Sales and Marketing and General Counsel to DuPont Merck’s International, Manufacturing and Generic Drug Divisions. Mr. Imasogie has also been a Price Waterhouse Corporate Finance Partner as well as a practicing attorney with a leading U.S. Law Firm, Schnader, Harrison, Segal & Lewis LLP, in the fields of corporate, corporate finance, taxation, and intellectual property law.
Mr. Imasogie holds LLM degrees from the London School of Economics and the University of Pennsylvania Carey Law School, where he is currently an adjunct Professor of Intellectual Property Law and Chair of the Law School’s Board. Mr. Imasogie is also a Trustee of the University of Pennsylvania and serves as a member of the Executive Committee of the Board.
In addition, he serves on the board of a number of financial institutions such as FS KKR Capital Corp. (NYSE: FSK) ($16 billion in assets under management), Haverford Trust Company (over $9.9 billion in assets under management) and Beltraith Advisors/StoneRidge Investments (over $2 billion in assets under management).
Prior to PIPV, Mr. Imasogie conceptualized and established GlaxoSmithKline Ventures and was its founding Vice President. Mr. Imasogie led GSK Ventures in concluding over 30 worldwide transactions within a 3-year period, in which he invested various GlaxoSmithKline (LSE: GSK) R&D non-progressed assets into various companies as the basis of starting new companies. Prior to GlaxoSmithKline, Mr. Imasogie was a Vice President for Product Development Strategy at SmithKline Beecham. Prior to SmithKline, Mr. Imasogie was the Founding Senior Vice President for Business Development and General Counsel at Endo Pharmaceuticals, Inc. (Nasdaq: ENDP), a publicly traded company with a peak market capitalization of $18 billion. Mr. Imasogie previously served as a DuPont Merck Vice President for International Sales and Marketing and General Counsel to DuPont Merck’s International, Manufacturing and Generic Drug Divisions. Mr. Imasogie has also been a Price Waterhouse Corporate Finance Partner as well as a practicing attorney with a leading U.S. Law Firm, Schnader, Harrison, Segal & Lewis LLP, in the fields of corporate, corporate finance, taxation, and intellectual property law.
Mr. Imasogie holds LLM degrees from the London School of Economics and the University of Pennsylvania Carey Law School, where he is currently an adjunct Professor of Intellectual Property Law and Chair of the Law School’s Board. Mr. Imasogie is also a Trustee of the University of Pennsylvania and serves as a member of the Executive Committee of the Board.
